UNICYCIVE THERAPEUTICS INC (UNCY)
US90466Y1038 - Common Stock
Unicycive Therapeutics Joins Russell Microcap® Index
LOS ALTOS, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
What's going on in today's session
Top movers analysis one hour before the close of the markets on 2024-06-25: top gainers and losers in today's session.
What's going on in today's session
Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and...
Friday's after hours session: top gainers and losers
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in...
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
– OLC Demonstrates Bioequivalence to Lanthanum Carbonate – – Additional Poster Highlights Key Features of OLC as Perceived by Renal Dieticians – LOS...
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024
UNCY stock results show that Unicycive Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unicycive Therapeutics (NASDAQ:UNCY) just reported results for the first quarte...
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
– On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024 – – Multiple Presentations on OLC...
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023
UNCY stock results show that Unicycive Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unicycive Therapeutics (NASDAQ:UNCY) just reported results for the fourth quart...
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
– Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney...
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
Unicycive Announces $50 Million Private Placement
Led by new investors Octagon Capital and Great Point Partners, LLC, with participation from new and existing investors including Logos Capital, Nantahala...
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
– Promising Preclinical Results in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial...
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
Topline Data Expected in Q2, 2024...
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
LOS ALTOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
New Data to be Presented on the Bioequivalence Study for OLC...
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
New Preclinical Data on UNI-494 in Acute Kidney Injury...
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
– Topline Data from OLC Pivotal Trial Expected in Q2 2024 –– OLC will target the multibillion-dollar hyperphosphatemia market – LOS ALTOS, Calif.,...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the trading week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday!
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
Study will Evaluate 60 Participants with Results Expected in Q2 2024...
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage...
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
Reached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to...
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics,...
The 7 Most Undervalued Penny Stocks to Buy in October 2023
Undervalued penny stocks offer tremendous return for investors with an appetite for risk but these shares are relatively safe as well.
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
Appointment adds decades of drug development experience from a seasoned executive
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
Appointment adds decades of drug development experience from a seasoned executive...
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...